

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	BRÖGMANN, Bianca et al.	Confirmation No.:	1884
Serial No.:	10/510,674	Art Unit:	1617
Filed:	May 23, 2005	Examiner:	JEAN-LOUIS, Samira JM
For:	PHARMACEUTICAL PREPARATION CONTAINING OXYCODONE AND NALOXONE	Attorney Docket No.:	Y2428-00162

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandra, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to References **A13-A14**, **B18-B19** and **C09-C21** which are listed on the accompanying Form 1449 entitled "Information Disclosure Statement By Applicant."

These references are being submitted because they have been submitted in related pending United States applications. Copies of References **A09-A12** are not submitted herewith pursuant to 37 C.F.R. §§ 1.98(a)(2)(i), since these references are U.S. patent documents. Copies of References **B18-B19** and **C09-C21** are submitted herewith. Applicants will furnish copies of any and all references to the Examiner upon request.


In accordance with 37 C.R.F. § 1.97(h), identification of the listed references is not to be construed as an admission that such reference is available as "prior art" against the subject application, as defined by 37 C.R.F. § 1.56(b). Applicants request that the

Examiner review the references identified on the attached Forms PTO/SB/8A and PTO/SB/8B, and that they be made of record in the file history of this application.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c). A fee in the amount of \$180.00, as set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is believed to be due. The Commissioner is authorized to charge such fee to Duane Morris LLP Deposit Account No. 04-1679.

Respectfully submitted,

Date: October 13, 2009

 31,636

(Reg. No.)

James G. Markey
Duane Morris LLP
1540 Broadway
New York, NY 10036
Tel. (212) 692-1000
Fax. (212) 692-1086

Enclosures